title: [Mifepristone inhibites the migration of endometrial cancer cells through regulating H19 methylation].
abstract: OBJECTIVE
  To investigate the effect and mechanism of mifepristone on the migration of human endometrial carcinoma cells.
  
  
  METHODS
  A human endometrial carcinoma cell line, Ishikawa cells, was cultured in vitro and treated with mifepristone at different concentrations. Wound healing assay was applied to detect the migration of Ishikawa cells. RT-PCR and methylation-specific PCR (MSP) were used to detect the levels of H19 mRNA and its DNA methylation. Western-blot was used to detect the expressions of HMGA2 and epithelial to mesenchymal transition (EMT) related proteins.
  
  
  RESULTS
  When treated with different concentrations of mifepristone for 48 hours, the width of scratch of the the control group, the 5 mg/L and the 10 mg/L mifepristone treatment groups were (4.18±0.07)mm, (4.68±0.07)mm, and(4.99±0.07)mm, respectively (P<0.05 for all) and treated with mifepristone for 72 hours, those were(3.46±0.07)mm, (4.29±0.07)mm, and(4.78±0.04)mm, respectively (P<0.05 for all). In the Ishikawa cells, mifepristone suppressed the transcriptional level of H19 through enhancing its promoter methylation, which resulted in inhibited expressions of HMGA2 and vimentin and increased expression of E-cadherin in a time- and concentration-dependent manner.
  
  
  CONCLUSIONS
  Mifepristone inhibits the migration of endometrial carcinoma cells partially through methylation-induced of transcriptional inhibition of H19, which results in the down-regulation of HMGA2 and vimentin and upregulation of E-cadherin.
authors.affiliation: Department of Obstetrics and Gynecology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, China.
authors.forename: Z Z
authors.initials: ZZ
authors.lastname: Lu
authors.affiliation: Department of Obstetrics and Gynecology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, China.
authors.forename: L
authors.initials: L
authors.lastname: Yan
authors.affiliation: Department of Obstetrics and Gynecology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, China.
authors.forename: H
authors.initials: H
authors.lastname: Zhang
authors.affiliation: Department of Obstetrics and Gynecology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, China.
authors.forename: M J
authors.initials: MJ
authors.lastname: Li
authors.affiliation: Department of Obstetrics and Gynecology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, China.
authors.forename: X H
authors.initials: XH
authors.lastname: Zhang
authors.affiliation: Department of Obstetrics and Gynecology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, China.
authors.forename: X X
authors.initials: XX
authors.lastname: Zhao
mesh_terms: D015703:Antigens, CD; D015820:Cadherins / Q000378:metabolism; D002277:Carcinoma / Q000473:pathology; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects*; D019175:DNA Methylation; D015536:Down-Regulation; D016889:Endometrial Neoplasms / Q000473:pathology*; D058750:Epithelial-Mesenchymal Transition; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D025743:HMGA2 Protein / Q000378:metabolism; D006801:Humans; D015735:Mifepristone / Q000494:pharmacology*; D011401:Promoter Regions, Genetic; D062085:RNA, Long Noncoding / Q000737:chemistry*; D012333:RNA, Messenger / Q000378:metabolism; D015854:Up-Regulation; D014746:Vimentin / Q000378:metabolism
chemical_list: D015703:Antigens, CD; C513384:CDH1 protein, human; D015820:Cadherins; C094335:H19 long non-coding RNA; D025743:HMGA2 Protein; D062085:RNA, Long Noncoding; D012333:RNA, Messenger; D014746:Vimentin; D015735:Mifepristone